Work

Abstract PS5-05-20: Real-world treatment patterns and outcomes in patients with HER2+ metastatic breast cancer after treatment with trastuzumab deruxtecan (T-DXd) in the US

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps5-05-20

Authors: S. M. Tolaney, S. Valliant, S. Hunter, O. Tymejczyk, A. Yu, J. Earla, E. Pang

Institutions: Dana-Farber Cancer Institute, Daiichi Sankyo (United States), Merck & Co., Inc., Rahway, NJ, USA (United States)

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129575833

Cites:

Cited by:

Related to: